Post-earnings recap
Reported
Thu, Oct 27, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report shows that while Alnylam Pharmaceuticals exceeded EPS expectations, the stock still fell by 3.49%. This decline may be attributed to broader market concerns and the lack of revenue data and guidance. Investors may be cautious as the company navigates current challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.58 | N/A | +14.87% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding market conditions. They reiterated their commitment to innovation and long-term strategies.
Management highlighted ongoing challenges in the market.
They emphasized a focus on long-term growth despite current setbacks.